An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 368-374

  Moore, David H ^a   Kauderer, James T ^b   Bell, Jeffrey ^c,d   Curtin, John P ^e   Van Le, Linda ^f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d RIVERSIDE METHODIST HOSPITAL   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Epithelial ovarian cancer; Gynecologic Oncology Group

Indexed keywords

CISPLATIN; PACLITAXEL;

AGE DISTRIBUTION; ALTERNATIVE MEDICINE; CANCER GRADING; CANCER PATIENT; CLINICAL PROTOCOL; DATA ANALYSIS; DATA BASE; DEMOGRAPHY; HISTOPATHOLOGY; HUMAN; INFORMED CONSENT; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; MEDICAL RECORD; OVARY CARCINOMA; PATIENT ATTITUDE; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; TREATMENT PLANNING;

EID: 3543121224     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.033     Document Type: Article

References (29)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics. CA Cancer J. Clin. 52:2002;23-47
2. Heintz A.P.M., Hacker N.F., Lagasse L.D. Epidemiology and etiology of ovarian cancer: a review. Obstet. Gynecol. 66:1985;127-135
3. Cramer D.W., Welch W.R. Determinants of ovarian cancer risk. J. Natl. Cancer Inst. 71:1983;717-721
4. Sparks J.M., Varner R.E. Ovarian cancer screening. Obstet. Gynecol. 77:1991;787-792
5. DePriest P.D., Gallion H.H., Pavlik E.J., Kryscio R.J., van Nagell J.R. Jr. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol. Oncol. 65:1997;408-414
6. Malkasian G.D., Melton L.J., O'Brien P.C., Greene M.H. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am. J. Obstet. Gynecol. 149:1984;274-284
7. Swenerton K.D., Hislop T.G., Spinelli J., LeRiche J.C., Yang N., Boyes D.A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet. Gynecol. 65:1985;264-270
8. Omura G., Blessing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer. 57:1986;1725-1730
9. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
10. Yancik R., Ries L.G., Yates J.W. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am. J. Obstet. Gynecol. 154:1986;639-647
11. Ganz P.A. Does (or should) chronologic age influence the choice of cancer treatment? Oncology. 6:1992;9S-45S
12. U. S. Bureau of the Census, Current Population Reports, series P-25, No. 1045.
13. Ries L.A.G., Kosary C.L., Hankey B.F., Harras A., Miller B.A., Edwards B.K. SEER Cancer Statistics Review: 1973-1993 (tables and Graphs). 1995;National Institutes of Health, Bethesda, MD
14. Hightower R.D., Nguyen H.N., Averette H.E., Hoskins W., Harrison T., Steren A. National survey of ovarian carcinoma: IV. Patterns of care and related survival for older patients. Cancer. 73:1994;377-383. [supplement]
15. Markman M., Lewis J.L., Saigo P., Hakes T., Rubin S., Jones W., et al. Impact of age on survival of patients with ovarian cancer. Gynecol. Oncol. 49:1993;236-239
16. Gershenson D.M., Mitchell M.F., Atkinson N., Silva E.G., Burke T.W., Morris M., et al. Age contrasts in patients with advanced epithelial ovarian cancer. Cancer. 71:1993;638-643. [supplement]
17. De Rijke J.M., Schouten L.J., Volovics A., Van Der Putten H.W.H.M. Age-specific differences in treatment and survival of ovarian cancer patients in the province of Limburg, the Netherlands, 1986-92. Int. J. Gynecol. Cancer. 8:1998;150-157
18. Alberts D.S., Dahlberg S., Green S.J., Garcia D., Hannigan E.V., O'Toole R., et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and stage IV ovarian cancer. Cancer. 71:1993;618-627. [supplement]
19. Edmonson J.H., Su J., Krook J.E. Treatment of ovarian cancer in elderly women: Mayo Clinic-North Central Cancer Treatment Group Studies. Cancer. 71:1993;615-617. [supplement]
20. Thigpen T., Brady M.F., Omura G.A., Creasman W.T., McGuire W.P., Hoskins W.J., et al. Age as a prognostic factor in ovarian carcinoma. Cancer. 71:1993;606-614. [supplement]
21. Balducci L., Lyman G.H., Ershler W.B. Geriatric oncology. 1992;151-159 JB Lippincott, Philadelphia
22. Karl R.C., Smith S.K., Fabri P.J. Validity of major cancer operations in elderly patients. Ann. Surg. Oncol. 2:1995;107-113
23. Newcomb P.A., Carbone P.P. Cancer treatment and age: patient perspectives. J. Natl. Cancer Inst. 85:1993;1580-1584
24. Goodwin J.S., Hunt W.C., Samet J.M. Determinants of cancer therapy in elderly patients. Cancer. 72:1993;594-601
25. Goodwin J.S., Samet J.M., Hunt W.C. Determinants of survival in older cancer patients. J. Natl. Cancer Inst. 88:1996;1031-1038
26. Balducci L., Mowrey K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology. 6:1992;62-68. [supplement]
27. Begg C.B., Carbone P.P. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer. 52:1983;1986-1992
28. Cornelison T.L., Reed E. Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age. Cancer. 71:1993;650-655. [supplement]
29. Guideline for the Study of Drugs Likely to be Used in the Elderly. 1989;Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD